UroGen Pharma to Present at Upcoming Investor Conferences

Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech firm focused on innovative urothelial cancer treatments, is set to present at two investor conferences in March 2023. The Cowen 43rd Annual Health Care Conference will feature a panel presentation on March 7 from 12:50-1:50pm ET. The Oppenheimer 33rd Annual Healthcare Conference will include a presentation on March 14 from 10:40-11:10am ET. Webcasts for both events will be accessible on UroGen's website, with replays available for 30 days. UroGen's products include JELMYTO and investigational treatment UGN-102.

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in March:

Cowen 43^rd Annual Health Care Conference — March 7-9, 2023

• Panel Presentation Date: Tuesday, March 7^th from 12:50-1:50pm ET
• Webcast Link: https://wsw.com/webcast/cowen132/panel12/2317014

Oppenheimer 33^rd Annual Healthcare Conference — March 13-15, 2023

• Presentation Date: Tuesday, March 14^th from 10:40-11:10am ET
• Webcast Link: https://wsw.com/webcast/oppenheimer27/urgn/2810892

Webcasts for both the Cowen and Oppenheimer presentations will be available via the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the Company’s website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product JELMYTO (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005965/en/

INVESTOR CONTACT:

Vincent Perrone

Senior Director, Investor Relations

vincent.perrone@urogen.com

609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano

UroGen Corporate Communications

cindy.romano@urogen.com

908-963-7827

Source: UroGen Pharma Ltd.

FAQ

When will UroGen Pharma present at the Cowen Healthcare Conference?

UroGen Pharma will present at the Cowen 43rd Annual Health Care Conference on March 7, 2023, from 12:50-1:50pm ET.

What is the date of UroGen Pharma's presentation at the Oppenheimer Healthcare Conference?

UroGen Pharma's presentation at the Oppenheimer 33rd Annual Healthcare Conference is scheduled for March 14, 2023, from 10:40-11:10am ET.

Where can I find the webcasts for UroGen Pharma's presentations?

Webcasts for both the Cowen and Oppenheimer presentations will be available on UroGen's website.

What is JELMYTO and how is it related to UroGen Pharma?

JELMYTO is a commercial product developed by UroGen Pharma for treating pyelocalyceal tumors using non-surgical means.

What innovative technology does UroGen Pharma utilize?

UroGen Pharma utilizes the RTGel™ reverse-thermal hydrogel technology to improve therapeutic profiles of existing cancer treatments.